Progyny, Inc. (NASDAQ:PGNY) Extends Liquidity And Accelerates Member Growth Ahead

Recent corporate actions and operating metrics point to sustained member engagement while technical momentum shows short-term consolidation. Fundamentals display improving cash generation alongside a valuation the WMDST model classifies as over-valued.

Recent News

On July 8, 2025 Progyny announced a revolving credit facility providing up to $200 million to enhance operational and financial flexibility. On July 10, 2025 the company partnered with ŌURA to incorporate wearable data into care-team decision support. On July 30, 2025 Progyny published a national study highlighting gaps between employee expectations and employer women’s-health benefits. On August 7, 2025 Progyny reported second-quarter 2025 results: record revenue of $332.9 million, $55.5 million in quarterly operating cash flow, and an increase to full-year guidance.

Technical Analysis

Directional indicators show limited trend strength: ADX at 15.8 signals no established trend, while both directional lines favor sellers—DI+ at 16.94 declining and DI- at 18.32 showing a dip-and-reversal—implying bearish directional pressure that may cap near-term rallies and support sideways trade around current levels.

MACD sits at -0.34 with the signal at -0.22 and a decreasing MACD trend; MACD below its signal line with negative momentum strengthens the near-term bearish pressure and reduces the probability of an immediate breakout above recent averages.

MRO at -3.58 (dip-and-reversal) indicates the price sits below the model target and therefore carries measurable reversion potential; that suggests any sustained selling could invite countervailing buying as momentum oscillators normalize.

RSI at 47.96 and falling places momentum below neutral and signals limited upside conviction until buyers push RSI back above 50; combined with a price that sits slightly under multiple short-to-medium moving averages, this favors range-bound action rather than trending moves.

Price sits at $21.46, marginally below the 200-day average $21.54 and well under the 50-day average $22.76 and the 26-day EMA $22.31; the price also trades just above the 1x lower Bollinger band ($21.41) and below the Ichimoku cloud (Senkou A $23.82 / Senkou B $23.37), which preserves a mildly bearish structural bias. Volume at ~898k runs below 10-day and 200-day averages, indicating limited conviction behind recent moves, while short-term beta (42-day) at 1.62 signals elevated sensitivity to market swings compared with its year-long beta of 0.59.

 


Fundamental Analysis

Revenue and cash flow: Reported total revenue reached $332,874,000 for the period. The revenue-growth metric reads 2.73%, while reported quarter-over-quarter revenue growth registers -68.22% and year-over-year revenue growth registers -70.84%; operating cash flow totaled $55,510,000 and free cash flow $50,241,000, with a free-cash-flow yield of 2.58%—above the industry peer mean free-cash-flow yield of 1.68%—supporting near-term liquidity.

Profitability and margins: Operating (EBIT) margin stands at 7.32%, slightly above the industry peer mean of 7.27%; that margin improved 7.56% year-over-year but contracted 1.90% quarter-over-quarter, indicating recent operating leverage while short-term margin pressure appeared. Return on equity measures 3.32% and return on assets 2.30%, consistent with modest returns on invested capital given scale.

Liquidity and leverage: Cash and short-term investments total $305,092,000 and the current ratio equals 2.70, above the industry peer mean current ratio of 1.38, while total debt sits at $25,505,000 and debt-to-assets at 3.35%—well below the industry peer mean—leaving balance-sheet flexibility intact. Interest coverage near 34.50 provides meaningful coverage of interest expense.

Valuation multiples and earnings: Trailing PE stands at 46.66 and forward PE at 113.65; price-to-book 3.78 sits above the industry peer mean price-to-book of 2.52, while price-to-sales at 5.85 exceeds the industry peer mean price-to-sales of 5.82 by a narrow margin. Reported EPS $0.48 beat the $0.43 estimate by $0.05, an EPS surprise of +11.63%, illustrating recent earnings execution even as forward EPS compresses to $0.19. WMDST values the stock as over-valued based on the current mix of valuation multiples and forward expectations.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2025-06-30
REPORT DATE: 2025-08-07
NEXT REPORT DATE: 2025-11-06
CASH FLOW  Begin Period Cash Flow 114.2 M
 Operating Cash Flow 55.5 M
 Capital Expenditures -5.27 M
 Change In Working Capital 519.0 K
 Dividends Paid
 Cash Flow Delta 23.3 M
 End Period Cash Flow 137.5 M
 
INCOME STATEMENT REVENUE
 Total Revenue 332.9 M
 Forward Revenue 79.4 M
COSTS
 Cost Of Revenue 253.9 M
 Depreciation 1.2 M
 Depreciation and Amortization 1.2 M
 Research and Development
 Total Operating Expenses 308.5 M
PROFITABILITY
 Gross Profit 79.0 M
 EBITDA 25.6 M
 EBIT 24.4 M
 Operating Income 24.4 M
 Interest Income 2.7 M
 Interest Expense
 Net Interest Income 2.7 M
 Income Before Tax 27.1 M
 Tax Provision 10.0 M
 Tax Rate 36.803 %
 Net Income 17.1 M
 Net Income From Continuing Operations 17.1 M
EARNINGS
 EPS Estimate 0.43
 EPS Actual 0.48
 EPS Difference 0.05
 EPS Surprise 11.628 %
 Forward EPS 0.19
 
BALANCE SHEET ASSETS
 Total Assets 761.0 M
 Intangible Assets 26.6 M
 Net Tangible Assets 488.4 M
 Total Current Assets 594.4 M
 Cash and Short-Term Investments 305.1 M
 Cash 132.5 M
 Net Receivables 271.9 M
 Inventory
 Long-Term Investments 8.6 M
LIABILITIES
 Accounts Payable 140.5 M
 Short-Term Debt
 Total Current Liabilities 220.4 M
 Net Debt
 Total Debt 25.5 M
 Total Liabilities 245.9 M
EQUITY
 Total Equity 515.0 M
 Retained Earnings 176.5 M
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 5.99
 Shares Outstanding 85.928 M
 Revenue Per-Share 3.87
VALUATION
 Market Capitalization 1.9 B
 Enterprise Value 1.7 B
 Enterprise Multiple 65.234
Enterprise Multiple QoQ 0.55 %
Enterprise Multiple YoY -40.708 %
Enterprise Multiple IPRWA high: 206.444
PGNY: 65.234
mean: 52.602
median: 47.277
low: -197.551
 EV/R 5.01
CAPITAL STRUCTURE
 Asset To Equity 1.478
 Asset To Liability 3.094
 Debt To Capital 0.047
 Debt To Assets 0.034
Debt To Assets QoQ -5.843 %
Debt To Assets YoY 735.91 %
Debt To Assets IPRWA high: 1.03
mean: 0.334
median: 0.32
PGNY: 0.034
low: 0.002
 Debt To Equity 0.05
Debt To Equity QoQ -11.015 %
Debt To Equity YoY 706.515 %
Debt To Equity IPRWA high: 4.335
mean: 1.17
median: 1.004
PGNY: 0.05
low: -1.392
PRICE-BASED VALUATION
 Price To Book (P/B) 3.781
Price To Book QoQ -5.555 %
Price To Book YoY -34.128 %
Price To Book IPRWA high: 14.27
PGNY: 3.781
mean: 2.52
median: 1.731
low: -7.254
 Price To Earnings (P/E) 46.656
Price To Earnings QoQ -63.666 %
Price To Earnings YoY -72.522 %
Price To Earnings IPRWA high: 272.225
mean: 63.567
PGNY: 46.656
median: 45.616
low: -187.532
 PE/G Ratio
 Price To Sales (P/S) 5.85
Price To Sales QoQ 1.358 %
Price To Sales YoY -32.065 %
Price To Sales IPRWA high: 28.322
PGNY: 5.85
mean: 5.816
median: 3.432
low: 0.067
FORWARD MULTIPLES
Forward P/E 113.652
Forward PE/G
Forward P/S 24.524
EFFICIENCY OPERATIONAL
 Operating Leverage 0.285
ASSET & SALES
 Asset Turnover Ratio 0.446
Asset Turnover Ratio QoQ -7.871 %
Asset Turnover Ratio YoY 9.591 %
Asset Turnover Ratio IPRWA high: 1.071
PGNY: 0.446
median: 0.385
mean: 0.336
low: 0.001
 Receivables Turnover 1.165
Receivables Turnover Ratio QoQ -3.838 %
Receivables Turnover Ratio YoY 13.184 %
Receivables Turnover Ratio IPRWA high: 12.053
mean: 4.148
median: 2.957
PGNY: 1.165
low: 0.065
 Inventory Turnover
Inventory Turnover Ratio QoQ
Inventory Turnover Ratio YoY
Inventory Turnover Ratio IPRWA
 Days Sales Outstanding (DSO) 78.345
CASH CYCLE
 Cash Conversion Cycle Days (CCC)
Cash Conversion Cycle Days QoQ
Cash Conversion Cycle Days YoY
Cash Conversion Cycle Days IPRWA
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 0.89
 CapEx To Revenue -0.016
 CapEx To Depreciation -4.373
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 515.0 M
 Net Invested Capital 515.0 M
 Invested Capital 515.0 M
 Net Tangible Assets 488.4 M
 Net Working Capital 374.0 M
LIQUIDITY
 Cash Ratio 1.384
 Current Ratio 2.697
Current Ratio QoQ 12.64 %
Current Ratio YoY 4.382 %
Current Ratio IPRWA high: 6.851
PGNY: 2.697
mean: 1.383
median: 0.838
low: 0.225
 Quick Ratio
Quick Ratio QoQ
Quick Ratio YoY
Quick Ratio IPRWA
COVERAGE & LEVERAGE
 Debt To EBITDA 0.998
 Cost Of Debt 1.733 %
 Interest Coverage Ratio 34.501
Interest Coverage Ratio QoQ 0.778 %
Interest Coverage Ratio YoY 17.745 %
Interest Coverage Ratio IPRWA PGNY: 34.501
high: 16.892
mean: 4.832
median: 3.159
low: -51.12
 Operating Cash Flow Ratio 0.186
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 52.607
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 4.199 %
 Revenue Growth 2.727 %
Revenue Growth QoQ -68.22 %
Revenue Growth YoY -70.844 %
Revenue Growth IPRWA high: 17.881 %
median: 4.575 %
mean: 3.484 %
PGNY: 2.727 %
low: -32.565 %
 Earnings Growth 0.0 %
Earnings Growth QoQ -100.0 %
Earnings Growth YoY -100.0 %
Earnings Growth IPRWA high: 250.0 %
PGNY: 0.0 %
mean: -19.36 %
median: -19.556 %
low: -291.304 %
MARGINS
 Gross Margin 23.725 %
Gross Margin QoQ 1.428 %
Gross Margin YoY 5.66 %
Gross Margin IPRWA high: 88.057 %
mean: 28.283 %
median: 27.838 %
PGNY: 23.725 %
low: -9.108 %
 EBIT Margin 7.317 %
EBIT Margin QoQ -1.904 %
EBIT Margin YoY 7.555 %
EBIT Margin IPRWA high: 35.873 %
PGNY: 7.317 %
mean: 7.271 %
median: 4.905 %
low: -48.909 %
 Return On Sales (ROS) 7.317 %
Return On Sales QoQ -1.904 %
Return On Sales YoY 7.555 %
Return On Sales IPRWA high: 31.023 %
mean: 8.156 %
PGNY: 7.317 %
median: 6.654 %
low: -49.228 %
CASH FLOW
 Free Cash Flow (FCF) 50.2 M
 Free Cash Flow Yield 2.58 %
Free Cash Flow Yield QoQ 2.748 %
Free Cash Flow Yield YoY 21.013 %
Free Cash Flow Yield IPRWA high: 12.561 %
PGNY: 2.58 %
mean: 1.683 %
median: 1.538 %
low: -16.999 %
 Free Cash Growth 6.975 %
Free Cash Growth QoQ -206.116 %
Free Cash Growth YoY -94.392 %
Free Cash Growth IPRWA high: 390.254 %
PGNY: 6.975 %
mean: -65.169 %
median: -66.168 %
low: -877.035 %
 Free Cash To Net Income 2.936
 Cash Flow Margin 12.32 %
 Cash Flow To Earnings 2.397
VALUE & RETURNS
 Economic Value Added 0.04
 Return On Assets (ROA) 2.295 %
Return On Assets QoQ 1.909 %
Return On Assets YoY 3.94 %
Return On Assets IPRWA high: 5.204 %
PGNY: 2.295 %
mean: 1.019 %
median: 0.951 %
low: -16.328 %
 Return On Capital Employed (ROCE) 4.506 %
 Return On Equity (ROE) 0.033
Return On Equity QoQ 3.071 %
Return On Equity YoY -8.052 %
Return On Equity IPRWA high: 0.111
PGNY: 0.033
median: 0.025
mean: 0.024
low: -0.486
 DuPont ROE 3.485 %
 Return On Invested Capital (ROIC) 2.989 %
Return On Invested Capital QoQ -26.866 %
Return On Invested Capital YoY -156.988 %
Return On Invested Capital IPRWA high: 7.951 %
PGNY: 2.989 %
median: 1.954 %
mean: 1.539 %
low: -22.946 %

Six-Week Outlook

Expect range-bound price action with a modest downside bias unless momentum indicators improve. Near-term technicals—negative MACD below its signal, declining RSI, and price below short-to-medium averages—favor consolidation or mild weakness. Offsetting this, MRO’s negative reading implies reversion potential and robust liquidity metrics reduce downside tail risk. Monitor for a meaningful uptick in volume or a MACD cross above the signal line to signal a shift in momentum; absent that, prepare for choppy trading in the coming six weeks with fundamental cash generation limiting deep breaks.

About Progyny, Inc.

Progyny, Inc. (NASDAQ:PGNY) designs comprehensive fertility and family building benefits solutions within the United States. The company crafts a fertility benefits solution that integrates a unique benefits plan design, personalized concierge-style member support services, and a selective network of fertility specialists. Progyny also develops Progyny Rx, an integrated pharmacy benefits solution, granting members access to necessary medications during their treatment. Additionally, Progyny provides assistance service programs through a reimbursement model, offering services such as adoption, surrogacy, doula support, and travel reimbursement for medical services. Established in 2008 and headquartered in New York, New York, Progyny initially operated under the name Auxogyn, Inc. before rebranding to Progyny, Inc. in 2015.



© 2025 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.